Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Core Insights - Aprea Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for APR-1051, an oral WEE1 kinase inhibitor aimed at precision oncology [1][2] - The company believes APR-1051 has unique characteristics that may differentiate it from other WEE1 inhibitors, including its molecular structure and selectivity [2] - If the IND is cleared, Aprea plans to initiate a Phase 1/2a clinical trial in the first half of 2024 to evaluate APR-1051's safety and efficacy [2] Company Overview - Aprea Therapeutics is a clinical-stage biopharmaceutical company based in Doylestown, Pennsylvania, focusing on precision oncology through synthetic lethality [3] - The company's lead program is ATRN-119, an ATR inhibitor for solid tumor indications, and it has completed all IND enabling studies for APR-1051 [3]